Sunovion CMO Dr Antony Loebel made company’s new CEO

pharmafile | March 5, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, CMO, Japan, medicine, psychiatry, sunovion 

Japanese drugmaker Sunovion Pharmaceuticals has made their current Chief Medical Officer (CMO) the company’s new Chief Executive Officer (CEO). Dr Antony Loebel will succeed Nobuhiko Tamura who has headed the company since 2014.

“I am proud of Sunovion’s accomplishments that include important clinical advances, as well as multiple advocacy and educational initiatives, while keeping patients at the center of everything we do,” said Mr Tamura. “Dr Loebel is a leader recognized for his contributions to science and medicine, guided by his dedication to patients. With Dr Loebel’s leadership and the passion and commitment of our employees, Sunovion is well-positioned to fulfill its bold vision to lead the way to a healthier world.”

A board certified psychiatrist, Dr Loebel joined Sunovion in 2007 from Pfizer, in which he served for seven years in the company’s senior leadership team.

The experienced pharma executive subsequently joined Sumitomo Dainippon Pharma Co, a Japanese firm which later acquired Sunovion, during which period he served as Vice President, Clinical Development. Dr Loebel has served in roles of increasing seniority within Sunovion for nearly nine years since the acquisition in 2010.

Having graduated from the Washington School of Medicine, Dr Loebel works as a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine, a Fellow of the American Psychiatric Association (APA) and a member of the American College of Neuropsychopharmacology (ACNP).

Dr Loebel currently serves on the Pharmaceutical Research and Manufacturers of America (PhRMA) BioMedical Advisory Council and was previously a member of the Massachusetts Biotechnology Council (MassBio) Board of Directors.

Commenting on his own appointment, Dr Loebel said: “This is an exciting time for Sunovion to advance our research and innovation and build on our track record of providing important new treatment options. I am honored to lead the dedicated employees of Sunovion who focus each day on serving and creating value for patients.”

Related Content

Working mum develops COVID-19 vaccination database in Tokyo

A 36-year-old former English teacher living in Tokyo, Japan, has launched her own healthcare database, …


Japan approves Moderna & AstraZeneca COVID-19 vaccines

A Japanese government panel has approved Moderna and AstraZeneca’s COVID-19 vaccines for use in adults, …


Incyte biliary tract cancer treatment approved in Japan

The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for …

Latest content